🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases per year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

As per data released by a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The trial included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have shared positive views. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered crucial to lessen the impact of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.